Elanco Animal Health Incorporated $ELAN Shares Sold by Skylands Capital LLC

Key Points

• Skylands Capital cut its stake in Elanco by 27.6% in Q4, selling 81,600 shares and retaining 213,600 shares worth about $4.83M, while institutional investors own roughly 97.48% of ELAN.
• Elanco beat quarterly expectations with $0.13 EPS versus $0.11 expected and revenue of $1.14B (up 12.2% YoY), and issued Q1 2026 guidance of $0.33–0.36 EPS and FY2026 guidance of $1.00–1.06.
• Analyst sentiment is broadly positive: MarketBeat lists an average rating of "Moderate Buy" and an average target of $27.90, with several firms recently raising ratings and targets up to $30.

Skylands Capital LLC cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 27.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 213,600 shares of the company's stock after selling 81,600 shares during the quarter. Skylands Capital LLC's holdings in Elanco Animal Health were worth $4,834,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ELAN. SJS Investment Consulting Inc. increased its holdings in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company's stock worth $28,000 after acquiring an additional 1,333 shares in the last quarter. Huntington National Bank lifted its holdings in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock valued at $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock worth $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock worth $43,000 after buying an additional 951 shares in the last quarter. Finally, Torren Management LLC purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth $46,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $22.08 on Tuesday. Elanco Animal Health Incorporated has a 52 week low of $9.32 and a 52 week high of $27.72. The company has a fifty day simple moving average of $24.03 and a two-hundred day simple moving average of $23.23. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The company has a market cap of $10.98 billion, a price-to-earnings ratio of -45.99, a price-to-earnings-growth ratio of 2.90 and a beta of 1.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the business posted $0.14 earnings per share. Elanco Animal Health's revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the topic of several research reports. Piper Sandler raised shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. Weiss Ratings reiterated a "sell (d+)" rating on shares of Elanco Animal Health in a report on Friday, March 27th. JPMorgan Chase & Co. raised their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Thursday, February 19th. Morgan Stanley boosted their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 25th. Finally, Citigroup began coverage on Elanco Animal Health in a research report on Wednesday, April 15th. They issued a "buy" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average target price of $27.90.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.